Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.45 |
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25556515 | 0.83 | MAOA (0.49) | MAOAMAOBSLC6A4CYP2C19CHRNA7 | |
| SCHEMBL22993595 | 0.83 | MAOA (0.49) | MAOAMAOBSLC6A4CYP2C19CHRNA7 | |
| SCHEMBL24746476 | 0.76 | MAOA (0.49) | MAOAMAOBSLC6A4HSP90AA1CHRNA7 | |
| SCHEMBL26745567 | 0.76 | MAOA (0.49) | MAOAMAOBSLC6A4HSP90AA1CHRNA7 | |
| SCHEMBL24253339 | 0.75 | MAOA (0.37) | MAOAMAOBSLC6A4CYP2C19HSP90AA1 | |
| SCHEMBL25556345 | 0.74 | MAOA (0.46) | MAOAMAOBSLC6A4CHRNA7DRD1 | |
| SCHEMBL20231738 | 0.74 | MAOA (0.53) | MAOAMAOBSLC6A4CHRNA7DRD1 | |
| SCHEMBL22782397 | 0.73 | MAOA (0.56) | MAOAMAOBSLC6A4CYP2C19CHRNA7 | |
| SCHEMBL22993218 | 0.73 | MAOA (0.47) | MAOAMAOBSLC6A4CHRNA7NMT1 | |
| SCHEMBL22864548 | 0.72 | MAOB (0.51) | MAOAMAOBSLC6A4CHRNA7DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-11613527-B2 | Enzyme inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| US-20220048894-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | MAOA 175/4885MAOB 71/4885SLC6A4 4581/4885 |
| US-11613527-B2 | Enzyme inhibitors | SERPINB1, KLKB1, SERPINE1 | MAOA 175/4885MAOB 71/4885SLC6A4 4581/4885 |
| US-20220048894-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | MAOA 175/4885MAOB 71/4885SLC6A4 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.